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 Managing HIV/AIDS presents challenges to public 
health policymakers, frontline workers, and researchers 
worldwide. A key strategy in the disease management is 
early diagnosis and rapid treatment initiation. While the 
technological field of point‐of‐care HIV/AIDS diagnostics has 
advanced significantly in the past two decades, several 
critical issues remain that hinder the deployment of point‐of‐
care testing devices in resource‐deprived settings. In this 
policy brief, we discuss these issues, including technological 
specifics of point‐of‐care CD4+ T‐cell counting approaches 
and requirements of deploying them. We also discuss 
cultural and religious concerns on the deployment. At the 
end of the brief, we propose a roadmap for the efficient and 
cost‐effective deployment and call for action to assemble 
multidisciplinary teams for the undertaking. We argue that 
joint effort must be taken to conduct research and 
development for low‐cost portable point‐of‐care testing and 
for tailoring the technology deployment and care delivery 
support system design for specific cohorts. 
 
Important Policy Issues Related to Point‐of‐Care  
(POC) Diagnostics for HIV 
 
 Early diagnosis and rapid initiation of treatment remains 
a key strategy to managing HIV/AIDS, which is still an 
important public health problem worldwide. Low‐cost 
portable POC tests have shown great promise of completely 
transforming the management (Yager et al. 2008), 
especially in resource‐limited settings where healthcare 
infrastructure is weak and the access to quality and timely 
care is a challenge.  These tests offer rapid results at or 
near the site of patient care, which allows for rapid initiation 
of appropriate treatment and/or establishment of linkages to 
care (Peeling and Mabey 2010). More importantly, POC 
tests can be simple enough to be used not only at 
conventional settings but also in settings with no laboratory 
infrastructure. POC tests are often more cost‐effective for 
the healthcare delivery system (Peeling and Mabey 2010), 
and can potentially empower patients to self‐testing with 
privacy and make informed decisions on their own. 
 
 Clinicians, researchers, and public health staff who work 
at the frontline of HIV/AIDS care and control have had 
access to an outstanding array of POC devices at their 
hospital.   However,  great  challenges  remain  in  deploying  
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these devices in an efficient and cost‐effective 
manner by considering the socioeconomic status 
of certain resource‐deprived regions, as well as 
cultural and religious factors in the regions. To 
resolve these challenges, there is an urgent need 
for assembling a multidisciplinary team of experts 
in the domains of bio‐sensing, operations research, 
public health, global policy, sociology, and religious 
studies. The joint effort must be made to answer 
the following policy questions related to diagnostics 
and treatment monitoring, which helps improve the 
delivery of needed care globally: 
 
a. Technology Research & Development 
Investment. Along which direction we can 
receive a higher return socioeconomically, 
between investing on AIDS medical research to 
improve current treatments (e.g., vaccine 
development as well as side effect reduction 
and adherence improvement of current drugs) 
and investing on testing deployment technology 
and systems research to improve current 
disease management in resource‐limited 
settings (e.g., POC testing development to aid in 
HIV diagnosis, disease staging, and treatment 
monitoring of HIV/AIDS). 
b. Technology Deployment Research and Care 
Delivery Support System Design. What POC 
HIV testing approaches can be extended for 
addressing the specific needs in resource‐
limited settings (e.g., antibody, antigen, nucleic 
acid‐based, CD4 count, etc.)? What are the 
necessary system requirements for efficient and 
cost‐effective deployment of the selected tests? 
c. Social, Cultural, and Religious Studies for 
Technology Deployment. What is an 
appropriate human right approach applied to 
POC HIV testing that pays due respect to ethical 
principles?  How to alleviate the social stigma 
and misconceptions so that the testing 
technology can be better deployed and the care 
delivery support system can be more effectively 
implemented? 
 
 The remainder of this policy brief is organized 
as follows. In Section 2, we introduce the 
background of HIV/AIDS to understand the current 
state of HIV/AIDS care and management, and 
motivate the needs for developing and deploying 
POC test methods. In Section 3, we focus on a 
discussion of the commercially available CD4  
T‐cell counting technologies and the roadblocks of 
deploying them efficiently and cost‐effectively in 
resource‐limited settings. In Section 4, we propose 
a roadmap for the success and call for 
multidisciplinary efforts to tackle the above policy 
questions. 
 
Background of HIV/AIDS 
 
	   Human immunodeficiency virus infection/ 
Acquired immunodeficiency syndrome (HIV/AIDS), 
a disease of human immune system, is caused by 
the human immunodeficiency virus (HIV) 
(Sepkowitz 2001; Fauci 2008). After HIV is in the 
body, it attacks and destroys CD4+ T‐cells, which 
are the part in the immune system that fights 
infection and diseases. The primary causes of HIV 
transmission are sexual contact and blood 
transfusion. In addition, a person can be infected 
through the sharing of dirty needles. A child can 
also get HIV from the mother during pregnancy, 
delivery, or breastfeeding (Rom and Markowitz 
2007, p. 745). Once a person is infected, there are 
three main stages of HIV infection: initial infection, 
clinical latency, and AIDS (Mandell et al. 2010, 
Chapter 121; US DHHS 2010). Following the 
contraction of HIV, a person may experience a 
brief period of influenza‐like illness (Cavendish 
2008, p. 25; Mandell et al. 2010, Chapter 118). 
This is typically followed by a prolonged period 
(i.e., 3 – 20 years and 8 years on average) without 
symptoms (Evian 2006, p. 29; Hicks 2006, p. 19; 
Elliot et al. 2012, p. 273). While there are typically 
few or no symptoms at first, many people 
experience fever, weight loss, gastrointestinal 
problems, and muscle pains near the end of this 
stage (US DHHS 2010). In the absence of 
treatment, around half the people with HIV will 
develop AIDS within 10 years (Mandell et al. 2010, 
Chapter 118). 
	  
	   AIDS is considered a global pandemic -- a 
disease outbreak that is present and actively 
spreading worldwide (Kallings 2008). It is a great 
public health challenge worldwide with significant 
socioeconomic impacts, as well as noticeable 
cultural and religious consequences. Prevention of 
HIV infection, primarily through safe sex and 
needle‐exchange programs, is a key strategy to 
control the spread of HIV/AIDS (Crosby and 
Bounse 2012). Meanwhile, even though there is no 
cure or effective HIV vaccine, antiretroviral 
treatment has been shown to be effective in
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slowing the disease progression, which may result 
in a near‐normal life expectancy (May and Ingle 
2011). As of 2010, more than 6.6 million people 
were receiving antiretroviral treatment in low and 
middle income countries (USAIDS 2011, pp. 1 ‐ 
10). Unfortunately, antiretroviral treatment 
medications are expensive (Orsi and d’almeida 
2010) and may be associated with side effects 
(Montessori et al. 2004). Hence it is critical to 
determine the timing of treatment initiation, 
especially in resource‐deprived areas. To make 
intelligent decisions at the individual patient level, it 
is important to have accurate CD4+ T‐cell counts. A 
collection of accurate test results will also lead to 
accurate modeling of disease progression and in 
turn intelligent development and modification of 





 As a disease, HIV/AIDS has threatened, if not 
devastated, many societies. It has led to nearly 30 
million deaths between recognizing it the first time 
in 1981 and 2009 (USAID 2010). As of 2010, 
approximately 34 million people worldwide have 
contracted HIV (USAIDS 2011, pp. 1-10). Of these, 
approximately 16.8 million are women and 3.4 
million are younger than 15 years old (USAIDS 
2011, pp. 1-10). It resulted in about 1.8 million 
deaths in 2010 (USAIDS 2011, pp. 1-10). 
   
 Sub‐Saharan Africa is the region that is most 
affected by HIV/AIDS. In 2010, an estimated nearly 
25 million people lived with HIV in this region, 
which constitute of more than two thirds of the HIV 
cases globally (USAIDS 2011, pp. 20-30). 
Approximately, 1.2 million (or 66% of worldwide) 
deaths occurred in the region (USAIDS 2011, 
pp. 20-30), which is equivalent to roughly 5% of the 
adult population in the region (USAIDS 2011, 
pp. 40-50). In contrast to other regions with high 
AIDS prevalence, women comprise a large portion 
of the deaths (nearly 60%) in sub‐Saharan Africa 
(USAIDS 2011, pp. 20 ‐‐ 30). It is also believed 
that 10% of all deaths among children were caused 
by HIV/AIDS. In addition, 14.8 million children have 
lost their parents to HIV/AIDS, accounting for 
almost 90% of the children orphaned by AIDS 
worldwide. South Africa has the largest HIV 
infected population in any country. Life expectancy 
has fallen in the worst‐affected countries due to 
HIV/AIDS; for example, it was estimated in 2006 
that the life expectancy in Botswana had dropped 
from 65 in the early 1980’s to 35 years (Kallings 
2008). 
 
 South and Southeast Asia is the second most 
affected, accounting for 4 million cases (or 12% of 
all people living with HIV) in 2010 and 
approximately a quarter million people died from 
HIV in the same year (USAIDS 2011, pp. 40-50). 
Even though AIDS has received great attention in 
the United State, its prevalence is still noticeable. 
In 2008, 1.2 million people in the United States 





 HIV/AIDS affects the economies of both 
individuals and countries (Bell et al. 2003; Mandell 
et al. 2010, Chapter 117).  The forecast is that it 
will probably cause the collapse of economies and 
societies in countries with a significant AIDS 
population. First, it affects the economic growth by 
reducing the availability of human capital (Bell et 
al. 2003; Mandell et al. 2010, Chapter 117). 
Without proper nutrition and necessary medicine 
care, large numbers of young people in many 
developing countries are falling victim to AIDS. 
They are not only unable to work, but also require 
significant medical care. The increased mortality 
leads to a reduced skill worker population, which in 
turns presents pressure on the country’s finance 
and derails its economy growth (Greener 2002). 
HIV/AIDS also weakens the mechanism that 
generates human capital, due to increased 
spending on medical care and death of parents 
with HIV/AIDS. The households that lose the 
parents will have less income to spend on 
education and other personal or family investment 
(Over 1992). In many heavily infected regions, 
AIDS has left behind many orphans (Greener 
2002; Mandell et al. 2010, Chapter 117). 
 
 In summary, much emphasis has been given in 
the past twenty years to the development of 
effective HIV/AIDS treatments. The current 
treatments are shown to be effective given timely 
disease staging and close treatment monitoring. 
However, these prerequisites are difficult to realize 
in resource‐limited settings. This explains why low‐
cost, portable, wireless‐enabled, easy‐to‐use POC 
testing is needed. 
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Cultural and Religious Factors 
 
 There are	   many misconceptions about 
HIV/AIDS such as the belief that it can be 
transmitted by casual non‐sexual contact 
(Sowadsy 1997). Other common misconceptions 
include that AIDS can be cured by sexual 
intercourse with a virgin (Flanagan 2001) and that 
HIV can infect only homosexual men and drug 
users (CDC 2008). These misconceptions lead to 
social stigma around the world to HIV/AIDS 
patients, which is a significant contributing factor 
for ineffective HIV/AIDS care (Pharris et al. 2011).  
A misconception directly related to CD4+ T‐cell 
counting is the belief that only a small number of 
CD4+ T-cells are infected by HIV, not enough to 
damage the immune system (Richman 2000). 
 
 The stigma exist in a variety of ways, including 
ostracism, rejection, discrimination, and avoidance 
of HIV infected people; compulsory HIV testing 
without prior consent or protection of 
confidentiality; violence against HIV infected 
individuals or people who are perceived to be 
infected with HIV; and the quarantine of HIV 
infected people (USAID 2006). Stigma‐related 
violence or the fear of violence prevents many 
people from seeking HIV testing, returning from 
their results, or securing treatment, possibly turning 
what could be a manageable chronic illness into a 
death sentence and perpetuating the spread of HIV 
(Ogden and Nyblade 2005). A recent study has 
found that as many as 40% of Americans who are 
HIV-positive do not begin a care regimen within the 
first 6 months after diagnosis (Mugavero 2008). 
 
 The disease has also become subject to many 
controversies involving religious beliefs (Mandel 
2011, Kerr 2012). A group of people and 
organizations continue to deny the causality 
between HIV and AIDS (Duesberg 1988). Some 
other forms of denial include rejecting the 
existence of HIV itself, or the validity of HIV testing 
and treatment methods (Smith and Novella 2007; 
Kalichman 2009). These denials, known as AIDS 
denialism (Kalichman 2009, p. 205), have incurred 
great human cost as they discourage HIV-positive 
people from using proven treatments (Cohen 1994; 
Watson 2006; Smith and Novella 2007).  In 
addition, AIDS denialism has had a significant 
political impact, especially in South Africa where 
the HIV/AIDS prevalence is alarmingly high 
(Chigwedere et al. 1999). Meanwhile, it is 
important to point out that many faith‐based 
organizations or churches have established social 
service and caring centers for HIV/AIDS patients, 
and the religious community could be mobilized to 
provide awareness education and technological 
dissemination. 
 
 In summary, POC testing is expected to help 
empower patients to make informed decisions 
through convenient testing with privacy and thus 
alleviate the difficulties arising from the 
aforementioned social stigma, cultural 
misconceptions, and religious concerns. On the 
other hand, the aforementioned concerns demand 
serious considerations when developing POC HIV 
testing technology and designing the associated 
care management information system, e.g., on the 
issue of information security. Finally, the social 
support provided by religious organizations is 
undeniable and should be taken into consideration 
when investigating the human factors in deploying 
POC HIV testing technology. 
 
CD4 T-Cell Counting and Antiretroviral Therapy 
 
 Many different tests are used in HIV diagnosis, 
disease staging, and treatment initiation. As 
HIV/AIDS has become a chronic rather than an 
acutely fatal disease in many areas of the world 
(Knoll 2007), it becomes critical to monitor the 
immune system functionality among HIV‐positive 
people and inform them with treatment decisions 
(e.g., initiation of antiretroviral therapy). Similar to a 
white blood cell count to determine infection, 
certain biomarkers help a clinician determine the 
status of an individual’s HIV status. These 
biomarkers are the T‐cell lymphocytes. A normal 
CD4 count varies between 500 and 1500 cells per 
microliter in blood (WHO 2007, pp. 6-16). Declining 
CD4 counts are considered to be a sign of 
progression of HIV infection (WHO 2007, pp. 6-16). 
Among HIV‐positive people, AIDS is officially 
diagnosed when the count drops below 200 per 
microliter based on the CDC classification (CDC 
2008).  
 
 When to start antiretroviral therapy is subject to 
debate (Sax and Baden 2009).  If antiretroviral 
therapy is administered too early, it may not lead to 
any improvement and this costly medicine is 
wasted. In addition, antiretroviral therapy may 
hinder a healthy individual’s natural immune 
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system. If it is administered too late, i.e., after the 
CD4 count drops below 50 per microliter, patients 
in general cannot be saved. A guideline developed 
by the U.S. Centers for Disease Control identifies 
persons with CD4 counts less than 200 per 
microliter as having AIDS (http://www.cdc.gov/hiv/ 
resources/guidelines/). Once CD4 count is below 
200, antiretroviral treatment is necessary for 
patient’s survival. It is also believed that beginning 
treatment at the level of 350 can reduce the risk of 
death (WHO 2010, pp. 19‐20). Furthermore, CD4 
count is needed to determine the appropriateness 
of treatment regimen given. Therefore, it is 
important to receive accurate and timely CD4 
counts for HIV‐positive patients. 
 
 Flow cytometry is the primary means for CD4+ 
T‐cell counting. In the 40 years since the invention 
of the cell sorter (Fulwyler 1965), a revolution has 
occurred within the world of immunology primarily 
driven by innovations of Len Herzenberg 
(Herzenberg et al., 1977; Loken and Herzenberg, 
L. A., 1975; Roederer et al., 1997) and others as 
cytometry matured into a powerful technology in 
medical research and clinical practice. However, a 
flow cytometer remains a precision instrument at 
present. First, it is costly, e.g., a typical flow 
cytometer costs USD $50,000 to $100,000. 
Second, it must be used by a trained operator and 
is meant to be installed in a lab in a stationary 
location. Finally, its power requirement 
necessitates highly controlled settings. As a result, 
POC flow cytometers have emerged as the next 
generation HIV/AIDS diagnostic and treatment 
monitoring devices, especially in resource‐limited 
settings. In the next section, we discuss the needs 
and gaps of the current systems and approaches. 
 
POC CD4 T-Cell Counting Technology:  Needs 
and Gaps 
 
 Clinicians, researchers, and public health staff 
who work at the frontlines of HIV care and control 
have had access to an outstanding array of POC 
diagnostics at their disposal, although uptake of 
these tests has varied across countries. POC tests 
for HIV include those used for screening, initial 
diagnosis, disease staging, treatment monitoring, 
and early infant diagnosis. An excellent survey of 
the current HIV diagnostics landscape has been 
published recently (Murtagh, 2011). 
 
 Between 30 and 40 million people in resource‐
deprived regions infected with the HIV virus need 
antiretroviral treatment. Two barriers exist. First, 
the cost is high; many efforts are at work to reduce 
these costs. Second, to receive therapy, each 
individual’s CD4 level must be monitored. Point‐of‐
care testing increases the likelihood of receiving 
the results quickly and making immediate 
treatment initiation decisions. The field of POC 
testing for CD4 count has advanced to consider 
over-the-counter, self-testing options and the use 
of multiplexed platforms that allow for simultaneous 
detection of infections associated with HIV, such 
as hepatitis B and C, and syphilis. 
 
 Unfortunately, flow cytometry is complex and 
expensive in today's technology‐focused world. 
While next‐generation ideas are important, they 
are not the solution for the present challenges on 
HIV/AIDS patient evaluation for CD4 levels in 
resource‐limited settings. Cytometers can and 
must be made inexpensively to deal with the global 
HIV/AIDS crisis. Furthermore, POC testing is often 
accomplished through the use of transportable, 
portable, and handheld instruments and test kits. In 
remote villages, some NGOs have begun 
transporting blood samples to and from central 
hospitals to determine the CD4 count. This can 
take weeks. Travel and testing is made more 
complex by the testing cycle in high‐volume 
hospitals, which can take hours or days. These 
processes also fail to provide a link between HIV 
determination, CD4 therapeutic qualification and 
therapy administration. With small handheld 
devices that can be used in rural and remote 
areas, patients in a matter of minutes can get 
confirmatory testing, obtain their CD4 count and, if 
qualified, receive immediate antiretroviral 
treatment. There are several moderately low cost 
systems available today (several sample systems 
are listed below). However, these systems are still 
intended for use in western countries and do not fit 
well in resource‐limited settings. 
 
• Pointcare (http://www.pointcare.net) has 
developed small instruments that are well 
suited for small hospitals.  They do not have 
any communication tools or technologies 
integrated and rely on an attached computer for 
computation and communication. 
• Partec (http://www.partec.com) has developed 
a large range of moderately low cost 
instruments, including a recent addition of an
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entirely portable instrument (around $14,000), 
which is battery operated and can achieve 
many of the needs in resource-limited settings. 
• Millipore (http://www.millipore.com) has 
developed a product called Millipore Muse, 
which is a low cost instrument ($12,000) that 
has the capacity for CD4 count in resource-
limited settings.  This small lightweight 
instrument can be operated on a car battery for 
short periods of time. 
• Becton Dickinson (http://www.bd.com) has a 
product called the FacsCount, which is the 
primary instrument currently used in Africa.  
However, it is neither small nor light (80 lbs), 
and its cost is high ($35,000). 
• Zyomyx (http://www.zyomyx.com) has a 
product that uses visual readout using a low 
cost testing device.  However, it is not clear if 
this technology will be accurate and robust.  
Further, the cost of individual tests may be 
significantly higher than affordable.  It does not 
have electronic readout or ability to transmit 
data points. 
 
 From the above discussion, we identify the 
following important features for the next-generation 
CD4 cell-counting tools.  In addition to such 
features as low-cost and portable, which are 
essential to resource-deprived geographically vast 
areas, these tools must be: 
 
• Robust.  It is often harsh environment weather-
wise in these resource-deprived regions (e.g, in 
sub-Saharan Africa). 
• Field-operated.  Health providers may not have 
a skill set equivalent to their counterparts in 
industrialized countries; laboratories may not 
be equipped as well as their counterparts 
either. 
• Batter-operated.  Many households in these 
resource-deprived regions may not have 
electricity. 
• Equipped with secured GPS and cell-phone 
technology.  Testing results can be managed 
with sufficient security measure in a centralized 
fashion, which enables epidemiological studies 
that are beneficial to HIV/AIDS public health 
policy development. 
 
 Furthermore, an overall system solution for 
supporting the care delivery must be sought by 
local health care providers in order to have the 
ability to decentralize these testing tools, keeping 
pace with the testing and therapeutically advances 
for HIV/AIDS.  For example, a fundamental 
problem is the lack of ability to integrate 
communication and tracking tools with current 
instruments.  There is a need to investigate, at the 
highest level, whether inclusion of such tools will 
be a necessary step before the problem of access 
to resource-limited countries will be overcome.  
This means more organized management, cloud 
architecture, cell phone linkages, and better 
relationships between manufacturers and CDC, 
Clinton Foundation, Gates Foundation, WHO, etc.  
It also means manufacturers need to develop more 
standards that allow data comparison, 
transmission, and management. 
 
A Proposal of POC CD4 Cell Counting 
Technology Deployment 
 
	   An ideal instrument should have the following 
detailed technological features: 1) it must be small, 
portable, low cost (<$5000) so as to lower the per 
test cost to below $2; 2) it should provide accurate 
simple readout with CD4 count, and percentage of 
total lymphocytes; 3) it should use fingerprick for 
sampling not venipuncture; 4) it should deliver 
testing location (GPS) to cell phone devices with 
coordinated central data collection service; 5) it 
should demand minimal training for accurate use 
by each individual or a field care provider; 6) it 
should be repairable within geographic location of 
use (or swapped out with new device); and 7) it 
can last a minimum of 8 hours on rechargeable 
battery or hand driven generator. To deploy the 
proposed instruments efficiently and cost‐
effectively, a system equipped with public cloud 
computing technology must be designed. Such a 
system must be secure, user‐friendly, as well as 
culturally and religiously conscious. 
 
 To ensure the feasibility in the research and 
development of the proposed technology and 
system solution, multidisciplinary teams must be 
assembled to investigate the policy questions of 
interest for specific regions with clear 
understanding of epidemiological and economic 
factors in the regions. The team must consist of 
experts in bio‐sensing, database technology, cloud 
computing technology, operations research, public 
health and international affairs. Proof‐of‐concept 
studies in a laboratory environment (e.g. agent‐
based simulation) must be carried out before field
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studies. Field studies must be carried out 
progressively with consideration of the political 
environment in each studied region. 
 
 With the necessary technological features, the 
POC are positioned to be the only potential 
solution to providing low cost diagnostics to 
mitigate the devastating results of AIDS in 
resource‐deprived regions. With smart e‐health 
system solutions and comprehensive feasibility 
testing, these tools are anticipated to create a 
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